SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending strongly as the stock breaks into new territory, fueled by news related to China's potential export restrictions on rare earth minerals. The community is bullish, anticipating further gains and a potential short squeeze, while also eyeing long-term prospects tied to deep-sea mining and critical mineral demand. Traders are closely watching for news catalysts and technical formations that could drive the stock higher.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

$SLV is trending as silver nears multi-decade highs, sparking community discussion around a potential short squeeze and anticipation of further gains. Some community members are discussing theories around market manipulation and speculating about triple-digit prices, while others highlight the potential for a significant breakout after years of price suppression. Investors are closely watching silver's momentum amid concerns about inflation and the dollar's stability.

Aventus Network

Aventus Network ($AVT) is trending, with community members discussing its potential and recent partnerships. Some are pointing to its low market cap and real-world applications in cargo management as reasons for optimism. Mentions of its integration with Polkadot and listing on Coinbase are also circulating.

Global Health Solutions Inc is an American company that works with partners to eliminate diseases that have plagued humanity for centuries and protect the health of populations by helping countries build strong health systems. The private company is located in the US. The company brings together key stakeholders around the world with a common goal to stop diseases and strengthen health systems through powerful partnerships. The company consists of programs and focus areas that cover a range of health issues including neglected tropical diseases, infectious diseases, vaccines, field epidemiology, public health informatics, health workforce development, and health ethics. The company's end goal is to eliminate diseases and protect the health of populations.

Turn Therapeutics Inc.

Turn Therapeutics Inc

Turn Therapeutics ($TTRX) is trending after its recent IPO, with the community discussing its potential for significant gains. Some traders are cautious, pointing to valuation concerns and possible formations on the minute chart, while others see it as the next stock poised for a substantial surge, drawing comparisons to other recent high-flying IPOs.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending as spot silver prices reach new highs, sparking excitement among investors. The community is actively discussing loading up on silver miners and anticipating further gains, drawing comparisons to gold's previous rallies. Some are pointing out the potential for silver miners to go mainstream, while others are debating realistic price targets.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending amid discussions of a potential short squeeze, driven by high short interest and growing optimism around its transition to AI/HPC data centers; the community is closely watching key resistance levels and anticipating a breakout. Positive sentiment is further fueled by Google's backing and potential approval of the Cayuga site, which could unlock significant capacity and revenue opportunities. Some traders are comparing it to the early stages of other AI plays.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

SERV is trending after announcing a strategic partnership with DoorDash, expanding its autonomous delivery robot service nationwide and outside of the Uber Eats ecosystem. Community members are discussing the potential for increased delivery volume and expansion into new markets, with some eyeing price targets. The stock is gaining traction as investors show interest in the autonomous last-mile delivery space.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is trending after reporting strong Q3 earnings, exceeding expectations and raising full-year guidance, boosting investor confidence and lifting the entire airline sector. The community is actively discussing whether to hold or sell, anticipating further gains and a potential rise to new highs. Corporate sales and premium revenue growth reflect strong demand, and the CEO expresses optimism for continued momentum.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending as investors speculate about a potential acquisition following increased M&A activity in the metabolic disease space, highlighted by the recent AKRO and MTSR deals. Community discussions revolve around potential buyout offers and the possibility of a short squeeze, with many believing VKTX is undervalued given its pipeline and recent data. The focus is now shifting towards MASH opportunities, adding another layer of potential value for the company.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense & Security Solutions is trending as investors discuss its potential as a key player in the evolving defense sector, particularly regarding drone and hypersonic technology. Community members highlight the company's innovative solutions, potential for partnerships, and rising defense spending as catalysts, while also speculating on possible acquisition targets. Some investors believe KTOS is currently undervalued compared to other defense giants, while others express concern about an overvalued status.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AstraZeneca (AZN) plans to list its ordinary shares on the New York Stock Exchange, replacing its existing U.S. listing of American Depositary Receipts (ADRs) on Nasdaq, the pharmaceutical giant announced on Monday.The move is part of the company’s efforts to expand its access to capital, including in the U.S. Nasdaq-listed ADRs of the company traded 1% higher in the pre-market session at the time of writing.Following the implementation of the new and harmonized listing structure, shareholders will be able to trade their interests in AstraZeneca ordinary shares across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York Stock Exchange (NYSE), the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-harmonise-its-listing-structure-across-the-london-stock-exchange-nasdaq-stockholm-and-new-york-stock-exchange.html">said</a>.Michel Demaré, Chair of AstraZeneca, stated that enabling a global listing structure would allow the company to reach a broader mix of global investors and make it even more attractive to all its shareholders, while remaining headquartered in the U.K. The plan will now be put to a vote on November 3.On Stocktwits, retail sentiment surrounding <a href="https://stocktwits.com/symbol/AZN">AZN stock</a> remained within the ‘bearish’ territory while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:578/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_6_49_19_AM_png_073b67d335.webp" alt="AZN's Sentiment Meter and Message Volume as of 6:49 a.m. ET on Sept. 29, 2025 | Source: Stocktwits" width="578" height="62"><figcaption>AZN's Sentiment Meter and Message Volume as of 6:49 a.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>AstraZeneca stated that the U.S. has the world’s largest and most liquid public markets by capitalization. The new listing structure will not alter the company’s status as a U.K.-listed, headquartered, and tax-resident company, the company added.In 2024, the United States accounted for 43% of AstarZeneca’s total revenue. The U.S. accounted for $23.23 billion in revenue while Europe accounted for 23% of total revenue, or $12.19 billion.In July, the company also announced a $50 billion investment in the U.S. by 2030, which would include the expansion of its research and development facility in Maryland, as well as manufacturing facilities for cell therapy in Rockville, Maryland, and Tarzana, California, among others.It had then stated that the investments would help it achieve its goal of reaching $80 billion in total revenue by 2030, with half of that revenue to be generated in the U.S. AZN shares are up by 13% this year but down by over 5% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-regulator-closes-probe-into-stellantis-24000-alfa-romeo-vehicles/chDM6PoR37x">US Regulator Closes Probe Into Stellantis’ 24,000 Alfa Romeo Giulia Vehicles</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The international biopharmaceutical company AstraZeneca office building in Shanghai, China on June 27, 2025. 

AstraZeneca Plans Ordinary Share Listing In US – Find Out More On The Harmonized Listing Structure

Michel Demaré, Chair of AstraZeneca, stated that enabling a global listing structure would allow the company to reach a broader mix of global investors and make it even more attractive to all its shareholders. 

Equity

Michel Demaré, Chair of AstraZeneca, stated that enabling a global listing structure would allow the company to reach a broader mix of global investors and make it even more attractive to all its shareholders. 


The National Highway Traffic Safety Administration (NHTSA) announced on Monday that it has closed its investigation into approximately 24,000 model year 2017-2018 Alfa Romeo Giulia vehicles.The U.S. auto safety regulator’s Office of Defects Investigation (ODI) had opened the probe in January 2024 to assess allegations of loss of motive power resulting from low-pressure fuel pump failures in certain Alfa Romeo Giulia vehicles. During its investigation, the NHTSA <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/inv/2024/INCLA-PE24003-86036.pdf">determined</a> that the vehicles were equipped with fuel delivery pumps supplied by Vitesco Technologies Germany GmbH.However, Stellantis issued a recall earlier this month covering 29,467 model-year 2017–2019 Alfa Romeo Giulia vehicles and 24,382 model-year 2018 Alfa Romeo Stelvio vehicles, all equipped with the suspect Vitesco fuel delivery pump. A remedy is under development, the company said.The NHTSA stated that it is closing its probe in light of the recall issued by Stellantis. However, the regulator said it reserves the right to take additional action if warranted.The NHTSA also noted that it is aware of 1,900 vehicles experiencing failures related to the issue, adding that it is aware of one crash associated with the issue, but no injuries, fatalities, or fires.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/STLA">STLA stock</a> remained within ‘bearish’ territory while message volume remained at ‘high’ levels.The NHTSA also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/inv/2024/INCLA-PE24006-86034.pdf">announced </a>on Monday that it has closed a probe into 226,250 model year 2018-2020 Dodge Journey vehicles, which was initiated in February 2024 due to complaints regarding the backup camera function. The company recently issued a recall to resolve the issue and noted that it will replace defective cameras in the recalled vehicles with an updated part that resolves the problem.STLA stock is down 29% this year and approximately 34% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-lobby-announces-new-website-to-connect-patients-with-manufacturer-direct-patient-programs/chDuciYR3JJ">Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Programs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A new Alfa Romeo Giulia on display at the Edmonton Motor Show on April 13, 2025, in Edmonton, Alberta, Canada. (Photo by Artur Widak/NurPhoto via Getty Images)

US Regulator Closes Probe Into Stellantis’ 24,000 Alfa Romeo Giulia Vehicles

The U.S. auto safety regulator’s Office of Defects Investigation (ODI) had opened the probe in January 2024 to assess allegations of loss of motive power resulting from low-pressure fuel pump failures. 

The U.S. Food and Drug Administration has sent a letter to Novo Nordisk (NVO) CEO Maziar Mike Doustdar regarding the company’s promotional communication featuring Oprah Winfrey, alleging that the video is false or misleading.The video originally appeared on ABC as a Primetime Oprah Special on March 18, 2024. It also subsequently appeared on Hulu. The video is a 42-minute special program hosted by Oprah Winfrey, featuring patient testimonials from individuals who struggle with obesity and excessive weight, including those who have used Novo’s Wegovy, Ozempic, or Victoza.The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/novo-nordisk-inc-716495-09092025">alleged</a> in a letter dated September 9 that the video misbranded Novo’s Wegovy, Ozempic, and Victoza, making its distribution violative. The video was also not submitted at the time of initial dissemination or publication as required by law, the agency said.“These violations are concerning from a public health perspective because the promotional communication creates a misleading impression regarding the safety of Wegovy, Ozempic, and Victoza, which are drugs with multiple serious, potentially life-threatening risks,” the agency said.The FDA also noted that obesity and type 2 diabetes are significant public health concerns in the U.S., and consumers who seek medical treatment for these conditions should receive truthful and nonmisleading information regarding the serious risks associated with the use of the drugs. While Novo’s Wegovy is used for weight management, its Ozempic and Victoza are used to treat type 2 diabetes.The FDA said that several advisory comments dated as long back as 2010 addressed draft promotional communications for Victoza with certain similarities to the aforementioned video. The agency expressed concerns that <a href="https://stocktwits.com/symbol/NVO">Novo</a> is promoting the three drugs in a manner that fails to present the serious risks of these drug products in a truthful and nonmisleading manner, despite the FDA’s prior comments.While the video includes numerous representations of the benefits of Wegovy, Ozempic, and Victoza made by representatives of Novo Nordisk, it omits important risk information or minimizes the risks associated with these drug products, the FDA said. Only four minutes in total were devoted to the important risks associated with GLP-1 drugs, such as Wegovy, the FDA said.The video also omits reference to how the drugs are contraindicated in patients with a personal or family history of Medullary Thyroid Cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2, it added. The omissions are exacerbated by statements from Amanda Velazquez, a paid consultant of Novo, made on the video, the FDA said.NVO stock is down by 33% this year and by 58% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-stock-tumbles-7-percent-after-fda-letter/chwyNFWRdzV">Hims &amp; Hers Stock Draws Investor Attention After Tumbling 7% – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’ 

The FDA alleged in a letter dated September 9 that the video misbranded Novo’s Wegovy, Ozempic, and Victoza, making its distribution violative. 

Novo Nordisk (NVO) announced on Tuesday that its new obesity treatment, Cagrilintide, reduced body weight by 11.8% after 68 weeks in a late-stage study.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916427">reported</a> an average weight loss of 12.5 kg, compared to 2.5 kg with the placebo, in the trial evaluating the efficacy and safety of once-weekly Cagrilintide 2.4 mg monotherapy, plus lifestyle intervention, for adults with obesity or overweight and a weight-related comorbidity without diabetes. The above levels of weight reduction were observed in participants who adhered to the treatment. Regardless of adherence, average weight loss with Cagrilintide was 11.5% compared to 3.0% with placebo after 68 weeks.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels. Shares of the company traded over 2% higher at the time of writing.<figure class="image"><img style="aspect-ratio:575/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_16_at_9_59_21_AM_png_2efadb4b5b.webp" alt="NVO's Sentiment Meter and Message Volume as of 9:59 a.m. ET on Sept. 16, 2025 | Source: Stocktwits" width="575" height="60"><figcaption>NVO's Sentiment Meter and Message Volume as of 9:59 a.m. ET on Sept. 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed disappointment that the stock rallied only 2-3% on good news.<stembedurl>https://stocktwits.com/King990/message/628811943</stembedurl>Cagrilintide works differently from currently approved GLP-1-based treatments for weight loss, including Novo’s Wegovy and Eli Lilly’s Zepbound. The new drug mimics the naturally occurring hormone amylin that helps control blood glucose levels and appetite by slowing gastric emptying, reducing glucagon secretion, and promoting satiety.The company also stated that approximately one in three participants receiving Cagrilintide achieved 15% or more weight loss, compared to approximately one in 20 participants receiving a placebo, when patients adhered to the treatment.Novo stated that the drug was well-tolerated, while adding that the most common side effects were gastrointestinal, including nausea, vomiting, diarrhoea, and constipation. These side effects were mainly temporary and mild to moderate, and 1% of participants discontinued the study due to nausea, compared to 0.1% of participants who received a placebo.“We’re excited that these data, the first phase 3 data of a next-generation amylin therapy, show promise, and we look forward to further investigating cagrilintide’s potential in the dedicated phase 3 RENEW programme,” said Martin Holst Lange, chief scientific officer and executive vice president of Research and Development at Novo Nordisk.Another late-stage programme investigating the efficacy and safety of Cagrilintide in people with obesity or overweight is due to start in the fourth quarter of this year.Separately, Bloomberg <a target="_blank" rel="noopener noreferrer nofollow" href="https://bloomberg.com/news/articles/2025-09-16/novo-plans-to-seek-us-approval-for-its-high-dose-obesity-shot?sref&amp;#61;8QBk7toa">reported</a> on Tuesday that Novo plans to seek U.S. regulatory approval for a high-dose version of Wegovy. Though the drugmaker hasn’t yet formally announced its U.S. plans, it intends to file for the U.S. Food and Drug Administration approval, said Lange at the European Association for the Study of Diabetes conference in Vienna, according to the report.NVO stock is down 34% this year and by about 58% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-regulator-opens-probe-into-174000-plus-tesla-model-y-vehicles/chwyiNgRdz5">US Regulator Opens Probe Into 174,000-Plus Tesla Model Y Vehicles – Check Out Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Says New Obesity Treatment Achieved 11.8% Body Weight Reduction In Late-Stage Study

The company reported an average weight loss of 12.5 kg, compared to 2.5 kg with the placebo, in a trial evaluating the efficacy and safety of once-weekly Cagrilintide 2.4 mg monotherapy. 

Automaker Stellantis NV (STLA) is recalling 53,849 vehicles in the U.S. over concerns that the fuel pump may fail, U.S. auto safety regulator National Highway Traffic Safety Administration (NHTSA) said on Tuesday.The NHTSA <a target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/rcl/2025/RCLRPT-25V586-8785.pdf">noted</a> that a fuel pump failure can result in a loss of fuel flow and drive power, increasing the risk of a crash. The recall includes model year 2017-2019 Alfa Romeo Giulia and model year 2018-2019 Alfa Romeo Stelvio vehicles. Some of the vehicles may have been built with a fuel delivery module (FDM) that contains internal components susceptible to heat, resulting in a loss of flow rate and, consequently, a reduction in motive power, it said. &nbsp;The remedy for the issue is currently under development. While letters notifying vehicle owners of the safety risk are expected to be mailed by the end of October, letters regarding the remedy will be sent once it becomes available, it added.The NHTSA noted that the recall follows an investigation initiated in January 2024. Stellantis has identified 437 customer complaints and field reports in North America that are potentially related to the issue. The company is also aware of five crashes and three injuries potentially related to the issue across all markets, it said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/STLA">STLA stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:580/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_16_at_7_09_28_AM_png_0b39e79559.webp" alt="STLA's Sentiment Meter and Message Volume as of 7:09 a.m. ET on Sept. 16, 2025 | Source: Stocktwits" width="580" height="59"><figcaption>STLA's Sentiment Meter and Message Volume as of 7:09 a.m. ET on Sept. 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed hopes for a rally this week, with the stock touching $10.<stembedurl>https://stocktwits.com/BullRunx100/message/628744748</stembedurl>STLA stock is down by about 26% this year and by about 37% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bloom-energy-stock-jumped-7-this-morning/chwyhXlRdyC">Bloom Energy Stock Jumped 7% This Morning – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stellantis Recalls Nearly 54,000 Vehicles In US Over Concerns Regarding Fuel Pump: But Retail Sees Stock Rallying To $10 This Week

The recall includes model year 2017-2019 Alfa Romeo Giulia and model year 2018-2019 Alfa Romeo Stelvio vehicles.

Eli Lilly (LLY) and Novo Nordisk (NVO) are reportedly expected to launch oral obesity pills by next year once they get regulatory approval in the U.S.According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company anticipates receiving results in the next few months from a head-to-head trial between its oral drug, Orforglipron, and Novo Nordisk’s oral Semaglutide. Daily pills would likely bring GLP-1s to more people, the report stated.&nbsp;The report noted that the primary aim of the study is to assess the effectiveness of the pills in lowering blood sugar levels in individuals with Type 2 diabetes, while also monitoring their impact on weight loss.“We wouldn’t have undertaken this head-to-head phase three randomized control trial unless we had a lot of confidence that orforglipron would fare well in comparison to oral semaglutide,” Skovronsky told CNBC.Retail sentiment on <a href="https://stocktwits.com/symbol/LLY">Eli Lilly</a> remained unchanged in the ‘neutral’ territory, with message volumes at ‘low’ levels, according to Stocktwits data.The report said that Skovronsky noted the results across trials, which did not directly compare the two drugs, should not be made, given Novo’s pill appears more effective with fewer discontinuations.&nbsp;Meanwhile, Novo’s Chief Scientific Officer, Martin Holst Lange, told CNBC in another interview that the data speaks for itself.Retail sentiment on <a href="https://stocktwits.com/symbol/NVO">Novo</a> remained in the ‘bearish’ territory, with chatter at ‘low’ levels, according to data from Stocktwits.The report explained that Novo’s upcoming obesity pill is a tablet form of its weekly injection, Wegovy. In contrast, Lilly’s pill, Orforglipron, is a completely new drug and different from its injectable treatment, Zepbound. According to Skovronsky, Zepbound remains the benchmark for effectiveness, helping patients lose over 20% of their body weight.The CNBC report noted that neither Novo’s pill nor Lilly’s oral drug is as effective as Zepbound. It added that Orforglipron&nbsp;has achieved around 12% weight loss at its highest dose, while oral Semaglutide&nbsp;has reached about 17%, prompting uncertainty over how many patients will choose a pill if it delivers less weight loss than injectable options.Skovronsky told CNBC that pills could eventually become the primary way that obesity would be treated, and that oral drugs could have a larger market share than shots.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rh-stock-sees-slew-price-target-cuts-from-wall-street-as-trump-tariffs-bite/chw8MrGRdDN">RH Stock Sees Slew Of Downgrades, Price Target Cuts From Wall Street As Trump Tariffs Bite</a>

While Lilly’s broader portfolio spans diabetes, cancer, and neuroscience treatments, investors remain largely focused on Mounjaro and Zepbound. 

Eli Lilly, Novo Nordisk Preparing To Introduce Obesity Pills Next Year In The US: Report

According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company expects trial results within months from a direct comparison between its oral drug Orforglipron and Novo Nordisk’s Semaglutide.

According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company anticipates receiving results in the next few months from a head-to-head trial between its oral drug, Orforglipron, and Novo Nordisk’s oral Semaglutide. 

Japanese carmaker Toyota Motor (TM) announced on Thursday that it is conducting a voluntary safety recall of approximately 591,000 vehicles in the U.S. due to concerns regarding the instrument panel.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://pressroom.toyota.com/toyota-recalls-certain-toyota-and-lexus-vehicles-5/">recall </a>involves certain Toyota Venza, Crown, Crown Signia, RAV4, GR Corolla, 4Runner, Camry, Grand Highlander, Tacoma, Highlander, and certain Lexus LS, RX, and TX vehicles.The 12.3-inch display on the instrument panel may be blank at startup, reducing the ability to see certain malfunction indicators and increasing the risk of a crash, the company stated.As for a fix, Toyota and Lexus dealers will inspect the vehicle and replace parts if needed, the company said, while adding that it will inform customers by mid-November.NYSE-listed shares of Toyota traded flat at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TM">TM stock</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘high’ levels.This year, through the end of July, Toyota sold nearly 6.1 million Toyota and Lexus brand vehicles worldwide. Sales in the U.S., including Hawaii, during the period were almost 1.5 million vehicles, surpassing any other single market and marking a 6.3% year-over-year growth. In Japan, the company’s home country, the company sold only 903,694 vehicles.However, the company produced only 800,178 vehicles in the U.S. during the period, while over 1.9 million were made in Japan. Earlier this week, it was <a href="https://stocktwits.com/news-articles/equity/markets/toyota-reshapes-us-operations-under-tariff-pressure-ev-su-vs-coming-to-kentucky-lexus-es-shifts-to-japan/chwNbuKRdHb">reported</a> that Toyota plans to produce two new three-row battery electric SUVs at its Kentucky plant as part of a strategy to streamline its U.S. operations. The changes follow the Trump administration's imposition of a 25% tariff on imported cars in April—a significant increase from the previous 2.5% rate. Following negotiations, a separate agreement reduced the rate to 15% for Japanese vehicles and parts.TM stock is up 2% this year and approximately 13% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/applied-digital-stock-advances-on-ai-optimism-retail-momentum-builds/chwNo3dRdvH">Applied Digital Stock Advances On AI Optimism, Retail Momentum Builds</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Raindrops are seen on Toyota car logo in Krakow, Poland on December 23, 2024. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Toyota Recalls Over Half A Million Vehicles In The US

The 12.3-inch display on the instrument panel may be blank at startup, which increases the risk of a crash, the company stated.

Magna International (MGA) said on Thursday that Philip D. Fracassa will succeed Patrick McCann as Executive Vice-President and Chief Financial Officer (CFO) of the company, effective immediately.McCann will step down from the company after a career spanning more than 26 years with Magna, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/11/3148417/0/en/Magna-Names-Philip-D-Fracassa-Chief-Financial-Officer.html">said</a>, while adding that the outgoing executive will remain in an advisory role until the end of February to enable a smooth transition.Fracassa previously served as Executive Vice President and CFO of The Timken Company since 2014, Magna said, adding that he brings extensive experience in the automotive and industrial sectors. He was also previously employed at automaker General Motors.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MGA">MGA stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:1364/122;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_9_07_06_AM_png_5286b70d90.webp" alt="MGA's Sentiment Meter and Message Volume as of 9:07 a.m. ET on Sept. 11, 2025 | Source: Stocktwits" width="1364" height="122"><figcaption>MGA's Sentiment Meter and Message Volume as of 9:07 a.m. ET on Sept. 11, 2025 | Source: Stocktwits</figcaption></figure>Fracassa’s appointment will be instrumental as the company delivers on its full-year outlook, the company said. Magna updated its full-year outlook in August and now expects total sales to be between $40.4 billion and $42 billion, and adjusted net income to be between $1.35 billion and $1.55 billion.In the second quarter, the company’s sales decreased 3% to $10.6 billion, as light vehicle production declined by 6% and 2% in North America and Europe, respectively. Adjusted and diluted earnings per share, however, rose 7% in the quarter to $1.44.Magna, the auto parts supplier, has about 164,000 employees across 338 manufacturing operations and 106 product development, engineering, and sales centres. The company’s results are dependent on light vehicle production by its customers, including Ford, GM, and Stellantis, in three key regions: North America, Europe, and China.Shares of the company rose 10% this year and by about 17% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/maze-therapeutics-stock-soars-after-150-million-private-placement/chwN1StRdvX">Maze Therapeutics Stock Just Shot Up 56% Pre-Market Today – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Magna International logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ford Supplier Magna International Appoints Former Timken Executive As CFO

Philip D. Fracassa will succeed Patrick McCann, who will step down after a career spanning more than 26 years with Magna. 

The U.S. auto safety regulator, the National Highway Traffic Safety Administration (NHTSA), announced on Monday that it has opened an investigation into 287,000 Chrysler Pacifica vehicles due to concerns about intermittent loss of electric power steering (EPS) during gradual turns.The probe includes model year 2017-2018 Pacifica minivans, including some plug-in hybrids. The NHTSA <a target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/inv/2025/INOA-PE25009-18789.pdf">said</a> that its Office of Defects Investigation (ODI) opened the probe to assess the scope, frequency, and potential safety consequences of alleged defects related to the EPS system.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/STLA">Stellantis stock</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels. Shares of the company traded 2% lower at the time of writing.<figure class="image"><img style="aspect-ratio:573/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_08_at_10_32_39_AM_png_1093ce31f5.webp" alt="STLA's Sentiment Meter and Message Volume as of 10:32 a.m. ET on Sept. 8, 2025 | Source: Stocktwits" width="573" height="62"><figcaption>STLA's Sentiment Meter and Message Volume as of 10:32 a.m. ET on Sept. 8, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user noted that the stock is “getting blasted” once again.<stembedurl>https://stocktwits.com/AanoldMcFace/message/627823094</stembedurl>The regulator said that ODI received 94 reports of a condition in which the steering system exhibits a sticking sensation during gradual turns, particularly when the steering wheel is positioned near the 11 o'clock or 1 o'clock position. During these events, increased steering effort is required to return the wheel to the center, the complainants alleged. Some also noted that this is followed by a sudden reactivation of EPS assistance, which may result in an oversteer condition.This behavior of the electric power steering could increase the risk of a crash, particularly at higher speeds, the NHTSA noted. However, the regulator is not aware of any crashes, fires, or injury incidents related to the alleged complaint.STLA stock is down 32% this year and about 43% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-biontech-updated-covid-vaccine-shows-robust-immune-response-in-late-stage-study/chwW6azRdrB">Pfizer, BioNTech’s Updated COVID-19 Vaccine Shows Robust Immune Response In Late-Stage Study – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

2017 Chrysler Pacifica is seen on Saturday, January 14, 2017. Staff photo by Christopher Evans (Photo by Christopher Evans/MediaNews Group/Boston Herald via Getty Images)

Stellantis Stock Slips After US Regulator Probes 287,000 Chrysler Minivans Over Concerns Regarding Electric Power Steer

The NHTSA stated that its Office of Defects Investigation (ODI) initiated an investigation to assess the scope, frequency, and potential safety implications of alleged defects related to the EPS system. 

Sanofi (SNY) announced on Thursday that its experimental drug, Amlitelimab, met all primary and key secondary endpoints in a late-stage study in adults and adolescents with atopic dermatitis (AD).The <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-09-04-05-00-00-3144170">study</a> enrolled 601 adults and adolescents aged 12 years and older with moderate-to-severe AD. Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically meaningful efficacy in skin clearance and disease severity compared to placebo at week 24. Furthermore, a progressive increase in efficacy was observed during the treatment period in patients who were dosed every four weeks as well as in those who were dosed every 12 weeks, the company said.The most common treatment-emergent adverse events, such as upper respiratory tract infection, were more common in the placebo arm compared to the Amlitelimab-treated arms of the study, it said.Shares of the company, however, traded 9% lower in the premarket session at the time of writing.According to a Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-sheds-13-billion-value-weak-trial-results-eczema-drug-2025-09-04/">report</a>, Jefferies analysts opined that the trial results fell short of those from an earlier trial and of rival biologic drugs. However, the drug's safety profile and convenient 12-week dosing regimen could still support its use.JPMorgan, meanwhile, noted that the data confirmed that Amlitelimab is less effective than Sanofi’s approved drug Dupixent, Reuters added. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SNY">SNY stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:578/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_04_at_7_50_44_AM_png_2f5aa98d10.webp" alt="SNY's Sentiment Meter and Message Volume as of 7:51 a.m. ET on Sept. 4, 2025 | Source: Stocktwits" width="578" height="61"><figcaption>SNY's Sentiment Meter and Message Volume as of 7:51 a.m. ET on Sept. 4, 2025 | Source: Stocktwits</figcaption></figure>Sanofi’s Dupixent is approved to treat atopic dermatitis in addition to asthma, chronic spontaneous urticaria, and other diseases. In the second quarter, Dupixent sales increased by 21.1% to €3.8 billion ($4.43 billion), and the company was expecting Amlitelimab to complement the blockbuster drug.The firm now looks forward to sharing additional late-stage results from the clinical development program of Amlitelimab in atopic dermatitis, said Houman Ashrafian, Executive Vice President, Head of Research &amp; Development at Sanofi.SNY stock is up 3% this year but down approximately 15% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/fda-says-no-advisory-commitee-meeting-required-for-aquestive-oral-epinephrine-film/chwd20pRdYB">FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Exchange Rate: €1= $1.17

Photo taken on April 15, 2025 shows the pharmaceutical factory of pharmaceutical company Sanofi in Hangzhou, Zhejiang province, China. (Photo credit should read CFOTO/Future Publishing via Getty Images)

Sanofi’s New Experimental Eczema Drug Meets Goals Of Late-stage Trial, But Wall Street Expected More

Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically meaningful efficacy in skin clearance and disease severity compared to placebo at week 24, the company said. 

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

DFAX
Dimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest DFAX News

DFAX Dimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF